The agenda outlines priority questions trials can address, aiming to generate public health benefits for at-risk children.

Agenus Inc. ( (AGEN) ) has released its Q3 earnings. Here is a breakdown of the information Agenus Inc. presented to its investors.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can ...

Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate ...

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 participants in total by early 2026, then plans to meet with ...

Machine Learning Models of Early Longitudinal Toxicity Trajectories Predict Cetuximab Concentration and Metastatic Colorectal Cancer Survival in the Canadian Cancer Trials Group/AGITG CO.17/20 Trials ...

Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

SHENZHEN, China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical ...

A collaborative effort across 14 clinical centers in Canada and Australia reports that pregnant women with type 1 diabetes ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the ...

Lactobacillus Paracasei, L. Reuteri, B. Lactis BL-04, and L. Salivarius set the standard for transparent oral health products ...